anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)
Drug Alias Namedual anti-CD19/anti-CD37 CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLeukocyte antigen CD37 modulatorsB-lymphocyte antigen CD19 modulators
TargetsLeukocyte antigen CD37B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHuazhong University Of Science And Technology
China Registration ClassN/A

Develop Information

Active CompaniesForevertek Biotechnology Co LtdHuazhong University Of Science And Technology
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A